Objective To determine the subjective response to iron therapy in non-anaemic women with unexplained fatigue. Design Double blind randomised placebo controlled trial. Setting Academic primary care centre and eight general practices in western Switzerland. Participants 144 women aged 18 to 55, assigned to either oral ferrous sulphate (80 mg/day of elemental iron daily; n=75) or placebo (n=69) for four weeks. Main outcome measures Level of fatigue, measured by a 10 point visual analogue scale. Results 136 (94%) women completed the study. Most had a low serum ferritin concentration; ≤ 20 g/l in 69 (51%) women. Mean age, haemoglobin concentration, serum ferritin concentration, level of fatigue, depression, and anxiety were similar in both groups at baseline. Both groups were also similar for compliance and dropout rates. The level of fatigue after one month decreased by − 1.82/6.37 points (29%) in the iron group compared with -0.85/6.46 points (13%) in the placebo group (difference 0.95 points, 95% confidence interval 0.32 to 1.62; P=0.004). Subgroups analysis showed that only women with ferritin concentrations ≤ 50 g/l improved with oral supplementation. Conclusion Non-anaemic women with unexplained fatigue may benefit from iron supplementation. The effect may be restricted to women with low or borderline serum ferritin concentrations.
Introduction
Fatigue is common in the general population. Prevalence rates of 14% to 27% have been reported in primary care, and in 1-2% of patients fatigue is the main reason for consultation. [1] [2] [3] [4] [5] [6] Women were three times more likely than men to mention fatigue in a study conducted in general practice. 7 Although the symptom of fatigue is related to iron deficiency anaemia, evidence is lacking for any association between iron deficiency and tiredness in the absence of anaemia. Iron deficiency associated with increased fatigue was, however, shown in a recent longitudinal study on women's health. 8 In a European study, about 20% of women of childbearing age had a serum ferritin concentration less than 15 g/l, and only 4% of these women had iron deficiency anaemia. 9 We examined the effect of iron therapy in women with unexplained fatigue in the absence of anaemia.
Methods
Our study was conducted in a primary care setting: an academic centre (57 patients) and eight private general practices (87 patients). Participants were recruited from December 1997 to March 2000. Women aged 18 to 55 were included if their main reason for consulting was fatigue. We excluded women with anaemia (haemoglobin concentration < 117 g/l), other obvious physical or psychiatric cause for fatigue, or chronic fatigue syndrome. Violations of the protocol detected after randomisation led to exclusion of women only in a complementary per protocol analysis. Reasons for these late exclusions had been determined beforehand: pregnancy diagnosed during the study period, haemochromatosis, physical or mental disorders identified after inclusion, and vitamins or iron supplements taken during the trial.
Randomisation, main outcome, and adherence to treatment Our study was a pragmatic randomised placebo controlled trial. Participants received either 80 mg/day oral long acting ferrous sulphate (Tardyferon; Robapharm, Boulogne) or placebo for four weeks. Iron and placebo were identical in appearance and taste and for dose regimen. Randomisation took place at an independent pharmacy, according to a pre-established list. Patients, caregivers, and investigators were blinded to treatment assignment until the end of the trial. Each drug package was coded with a unique number according to the randomisation schedule and then posted to the relevant practice. The codes were held by the pharmacist and remained unbroken until the analyses were completed. The main outcome was the level of fatigue perceived by patients, assessed at baseline and after one month on a 10 point visual analogue scale, ranging from 1 (no fatigue at all) to 10 (very severe fatigue). Also used was a validated 24 item self admin- 10 Levels of depression and anxiety were examined as additional outcomes. Each item was scored on a visual analogue scale. A cumulative score was obtained for each dimension by adding the eight item scores (range 0-40). The patients were asked about any potential side effects and intercurrent physical, psychological, and haemorrhagic events. Serum ferritin concentration and adherence to treatment were measured and considered as intervening variables. A complete blood count was obtained at baseline, and the serum ferritin concentration was measured by chemoluminometric immunoassay. Clinicians could order other tests to rule out any disorder to explain the fatigue. Serum ferritin concentration was measured after one month in those patients whose initial value was ≤ 20 g/l.
Adherence to treatment was measured by an electronic device (MEMS; Aardex Europe, Switzerland), which recorded the date and time that the pill container was opened.
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Unused pills were also counted. Adherence was quantified by dividing the number of times the device was opened by the total number of days of observation. Patients were asked not to take over the counter vitamin or iron supplements.
Statistical analysis
An estimated sample size of 63 patients was needed to detect a one point difference between the groups on the visual analogue scale. The calculation included an estimated standard deviation of two points for a two tailed test ( =0.05, power=0.80). We calculated changes in symptom levels and scores over time for each patient by subtracting the results at follow up from those at baseline. The principal analysis was performed according to an intention to treat protocol. Tests performed were two sample t tests, 2 tests, and linear regression analyses. A per protocol analysis was also conducted.
Results
In 366 women, fatigue was the main reason for consulting; 222 were excluded because of psychiatric disorders (110 women), physical disorders (61), refusals (16) , or other reasons (35). Of the 144 patients enrolled, 136 (94%) completed the intervention, seven (5%) were lost to follow up, and one withdrew because of nausea and vomiting (figure). The groups had similar characteristics at baseline (table 1) . Low serum ferritin concentrations were common: ≤ 50 g/l in 115 (85%) patients and ≤ 20 g/l in 69 (51%) patients.
Scores for anxiety and depression were low in both groups.
The mean decrease in the overall intensity of fatigue between zero and one month was higher in the iron group than in the placebo group ( − 1.82 (SD 1.7) v − 0.85 (2.1) points, difference 0.95 points 95% confidence interval 0.32 to 1.62, P=0.004; table 2). By choosing a cut-off point of 50 g/l, we found that there was no quantitatively significant response greater than 50 g/l (P=0.64). The iron group showed the largest decrease in the cumulative score for fatigue ( − 7.5 (8.0) v − 4.6 (7.5) points, difference 3.0 points, 0.3 to 5.6, P=0.03). The difference for depression was not statistically different between the two groups ( − 2.1 (6) v − 1 (7) points, P=0.31), whereas a greater decrease in anxiety was observed in the iron group ( − 1.7 (6) v 1.3 (6), P=0.003).
After adjustment for age, initial levels of depression and anxiety, and serum ferritin concentration in a multiple linear regression analysis, iron supplementation was the most important variable to be associated with the decrease in the overall intensity of fatigue, an effect corresponding to − 1 point on the visual analogue scale. Younger age was also associated with a larger decrease in the intensity of fatigue.
A multiple linear regression analysis in the iron group showed that age, initial levels of depression and anxiety, serum ferritin concentration, and haemoglobin concentration were not predictive of the mean decrease in the overall intensity of fatigue. The best predictor of response was the amount of pills consumed in the iron group, but this was not so in the placebo group.
Compliance and dropout rates were similar in both groups: 95% (12 ) v 98% (9), P=0.25) for compliance and 4 of 75 (5%) v 4 of 69 (6%) for dropout rates in the iron arm and placebo arm, respectively. After the intervention, serum ferritin concentrations were highest in the iron group (21.0 (SD 9.2) v 13.7 (6.9), P < 0.001). After exclusion of five patients, a per protocol analysis was no different from the intention to treat analysis. Flow of participants through study
Discussion
To our knowledge this is the first randomised clinical trial in women of childbearing age (18 to 55 years) to show that iron supplementation could have an effect on fatigue in the absence of anaemia. The effect may, however, be restricted to women with low or borderline serum ferritin concentrations. One trial found that 35 women with lassitude or poorly defined symptoms but without anaemia benefited from iron rather than placebo. 12 Adolescent females have been shown to benefit from iron supplementation: iron improved lassitude, ability to concentrate in school, and mood in one study, and in another study supplementation with 260 mg elemental iron daily improved verbal learning and memory. 13 14 In a non-randomised comparison of Australian women, fatigue decreased and quality of life increased with iron supplementation or a diet high in iron. 15 Women with fatigue often associate their symptoms with psychosocial stressors and not a possible emotional or biomedical cause. 4 16 17 Conversely, medical investigators tend to associate fatigue with emotional causes and more rarely with biomedical causes. 4-6 16 18 We found that iron deficiency may be an under-recognised cause of fatigue in women of childbearing age. Thus, identifying iron deficiency without anaemia as a potential cause of fatigue is important. It may avoid the inappropriate attribution of symptoms to putative emotional causes or life stressors and thereby reduce unnecessary use of healthcare resources. Instituting iron therapy early may also improve quality of life. 8 We found a significant response only in the patients with a baseline serum ferritin concentration ≤ 50 g/l. This suggests that iron deficiency could be present even with a "normal" concentration of serum ferritin. Indeed, the lower limit for serum ferritin concentration is controversial: iron stores in the bone marrow may serve as a better indicator of iron deficiency. 19 One study compared serum ferritin concentrations with iron stores in the bone marrow and found that a serum ferritin concentration of 50 g/l was associated with a 50% chance of iron deficiency occurring in the bone marrow. 20 The lower reference limits for serum ferritin and haemoglobin concentrations have been considered too low for women. 21 The authors of that study advocate the adoption of the same reference values for both men and women that "would be expected to have fundamental and positive implications for women's health and welfare." Our study indirectly supports their conclusion by showing that women can benefit from iron supplementation even if their red blood cell counts are considered normal.
Iron deficiency even in the absence of anaemia is associated with decreased activity of iron dependent enzymes and therefore affects the metabolism of neurotransmitters. 22 23 In people with iron deficiency anaemia the related symptoms will disappear more quickly than the accompanying increase in haematological indices. 24 This suggests that some cellular functions are affected by iron treatment independently of haemoglobin concentration. We did not, however, measure haemoglobin concentration after exposure to iron and therefore did not assess whether people who had low but normal haemoglobin concentrations had an increase in haemoglobin concentration that could be associated with a decrease in fatigue.
Limitations of study
Our study has several limitations. Firstly, blinding for group assignment is an important issue, especially with iron, because of the side effects. It was not possible to correct for the change in stool colour by adding bismuth to the placebo because bismuth is an active substance. To minimise the side effects we used a low dose iron sulphate taken with breakfast. Participants in both groups were also told that their drug could colour stools. We did not ask the participants to guess their group assignment. In a recent placebo controlled trial no significant differences in guesses about treatment were found between iron and placebo groups despite the elemental iron dose used being three times that of our study. 14 We found no difference in compliance between the two groups suggesting that the patients did not recognise that they had been assigned to placebo. Secondly, we did not have a procedure to control recruitment of all consecutive eligible patients, because this would have been difficult to apply in a busy clinical practice. Thirdly, ferritin concentration was the only measure of iron status in the study because it is considered the best non-invasive indicator of iron storage. 20 Finally, our primary outcome focused on fatigue, a patient centred subjective measure.
What is already known on this topic
Unexplained fatigue is common in young women Iron deficiency is highly prevalent among women of childbearing age Iron therapy is a well established treatment for fatigue in the presence of iron deficiency anaemia but not in the absence of anaemia
What this study adds
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